NexImmune, Inc. (NEXI)
- Previous Close
3.0900 - Open
3.1150 - Bid --
- Ask --
- Day's Range
3.0400 - 3.2000 - 52 Week Range
1.2500 - 28.6950 - Volume
14,019 - Avg. Volume
28,328 - Market Cap (intraday)
4.387M - Beta (5Y Monthly) 1.98
- PE Ratio (TTM)
-- - EPS (TTM)
-24.1100 - Earnings Date Aug 8, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It provides NEXI-004 which is in preclinical stage for EBV related diseases; and NEXI005 designs for patient with specific targets for solid tumors. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
www.neximmune.comRecent News: NEXI
Performance Overview: NEXI
Trailing total returns as of 6/6/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NEXI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NEXI
Valuation Measures
Market Cap
4.39M
Enterprise Value
-190.32k
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.48
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-69.71%
Return on Equity (ttm)
-196.48%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-25.86M
Diluted EPS (ttm)
-24.1100
Balance Sheet and Cash Flow
Total Cash (mrq)
4.45M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-9.96M